We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Two cycles of plasma rich in growth factors (PRGF-Endoret) intra-articular injections improve stiffness and activities of daily living but not pain compared to one cycle on patients with symptomatic knee osteoarthritis.
- Authors
Vaquerizo, Víctor; Padilla, Sabino; Aguirre, José Javier; Begoña, Leire; Orive, Gorka; Anitua, Eduardo
- Abstract
<bold>Purpose: </bold>To assess the clinical efficacy and safety of a treatment based on one cycle versus two cycles of intra-articular injections of plasma rich in growth factors (PRGF-Endoret) on patients with knee osteoarthritis (OA).<bold>Methods: </bold>Ninety patients with knee OA were included and evaluated. A total of 48 patients received one cycle (OC group) (3 injections on a weekly basis), while 42 patients received two cycles of PRGF-Endoret (TC group) spaced 6 months between them. Patients were evaluated with LEQUESNE and WOMAC scores before treatment and after 48 weeks. Safety assessment was also performed.<bold>Results: </bold>A significant reduction of all assessed outcome measures was shown for both groups at 48 weeks compared with baseline values (P < 0.001). Patients of TCs group showed a significantly higher reduction (P < 0.05) in WOMAC stiffness subscales. Regarding LEQUESNE INDEX, a significantly higher reduction was observed in the TC group in all subscales except in pain score. In the maximum walking distance subscale (MCD), the improvement rate was 31.8% higher for the TCs group compared with the OC group (P < 0.01). In addition, the TC group showed a significant improvement in LEQUESNE activities of daily living (ADV) and global subscales of 14.7 and 11.8% (P < 0.05) higher, respectively, than the OC group.<bold>Conclusions: </bold>Treatment with two cycles of PRGF did not show a significantly higher pain reduction compared with one cycle treatment. However, two cycles of PRGF showed a significant improvement in WOMAC stiffness, LEQUESNE MCD, LEQUESNE ADV and LEQUESNE global subscales. Therefore, patients treated with two cycles present an improvement in quality of life.<bold>Level Of Evidence: </bold>II.
- Subjects
OSTEOARTHRITIS treatment; GROWTH factors; ACTIVITIES of daily living scales; PAIN management; REGENERATION (Biology); INTRA-articular injections; HEALTH outcome assessment; THERAPEUTICS; KNEE diseases; BLOOD plasma; CLINICAL trials; COMPARATIVE studies; RESEARCH methodology; MEDICAL cooperation; PAIN; QUALITY of life; RESEARCH; ACTIVITIES of daily living; EVALUATION research; PAIN measurement; TREATMENT effectiveness; PLATELET-rich plasma
- Publication
Knee Surgery, Sports Traumatology, Arthroscopy, 2018, Vol 26, Issue 9, p2615
- ISSN
0942-2056
- Publication type
journal article
- DOI
10.1007/s00167-017-4565-z